Revolution Medicines seeks to bolster case for its lead cancer drug
Revolution Medicines on Saturday presented updated data to bolster the case for its lead cancer drug — designed to stop tumor growth by throttling back mutations in a common cell-signaling pathway.
The drug, called RMC-4630, won’t shrink tumors very much on its own. The drug’s main purpose will be as a backbone of combination treatments. The first test of this pairing strategy will come toward the end of the year, when Amgen reads out results of a study using RMC-4630 to boost the efficacy of sotorasib, its mutant KRAS-blocking lung cancer drug.
Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!
What is it?
STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis.
Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.
What’s included?
- Daily reporting and analysis
- The most comprehensive industry coverage from a powerhouse team of reporters
- Subscriber-only newsletters
- Daily newsletters to brief you on the most important industry news of the day
- STAT+ Conversations
- Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
- Exclusive industry events
- Premium access to subscriber-only networking events around the country
- The best reporters in the industry
- The most trusted and well-connected newsroom in the health care industry
- And much more
- Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
Published at Sat, 10 Apr 2021 18:00:00 +0000